Ravi Kiron

KineMed, Inc. develops and commercializes biomarker platform technology. It provides dynamic proteomics platform, a functionally interpretable systems biology platform. The company was founded by David M. Fineman and Marc K. Hellerstein in February 2001 and is headquartered in Emeryville, CA.

Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.

EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA.

C2N Diagnostics LLC is a private company that focuses on mechanism-based approaches to prevent or stop the progression of human neurological disorders. The company is based in St. Louis, MO. The company's lead commercial product, PrecivityAD™, is a mass spectrometry-based test that measures in blood multiple analytes including a?42, a?40, and apolipoprotein e isoforms. This test predicts brain amyloid plaques as determined by PET scan results and received a breakthrough device designation from the Food and Drug Administration in early 2019. C2N Diagnostics aims to bring accurate, widely accessible, and cost-effective blood tests to the clinic for the betterment of patient care and brain health monitoring in the field of neurodegeneration and Alzheimer's disease. The company was founded by Ravi Kiron, Joel Bennett Braunstein, Ilana Fogelman. Joel Bennett Braunstein has been the CEO since incorporation.

ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California.